IDH1 and myelodysplastic syndrome: In addition, the ivosidenib/venetoclax combination, in a clinical trial, was administered as a therapeutic combination alone or in triplet with azacytidine in IDH1-mutated MDS, ND, and R/R AML with promising results [141].